Mohammad Alashqar Shares Novel Antithrombin-Targeting Therapy for Hemophilia A and B
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
“Grateful to share that my review paper, ‘Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors,’ has been published online today (12/26)
Sincere thanks to everyone who supported me throughout this journey—especially Dr. Milap Nahata for his mentorship, guidance, and invaluable feedback. This work would not have been possible without such support.
Looking forward to continuing contributions to hemophilia and thrombosis research.
Title: Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors
Authors: Mohammad Alashqar, Milap Nahata
Read the article.”
Deepen your hematology knowledge with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS